Analyst Ranking
Top 24%
#1273 out of 5493 analysts
Average Return
+5.06%
Win Rate
44%44 out of 101
Risk vs Reward
Poor
Good

Paul Matteis's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Alto Neuroscience IncANRO
+213.47%$4.53$14.20
2024-11-13 -
2025-11-12
Strong Buy
Lb Pharmaceuticals IncLBRX
+192.40%$15.14$44.27
2025-10-06 -
2026-08-13
Strong Buy
Dyne Therapeutics IncDYN
+161.22%$9.85$25.73
2025-07-31 -
2026-07-30
Strong Buy
Uniqure NvQURE
+138.28%$19.75$47.06
2025-12-11 -
2026-08-13
Strong Buy
Sionna Therapeutics IncSION
+130.34%$14.80$34.09
2025-03-04 -
2026-03-03
Strong Buy

Paul Matteis's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Neurocrine Biosciences IncNBIX
9Strong Buy$215.00+42.55%Maintains
14 days ago
Alnylam Pharmaceuticals IncALNY
11Strong Buy$318.00+40.01%Maintains
14 days ago
Acadia Pharmaceuticals IncACAD
8Hold$25.00-11.91%Maintains
24 days ago
Alkermes PLCALKS
6Strong Buy$63.00+27.40%Reiterates
25 days ago
Definium Therapeutics IncDFTX
2Strong Buy$60.00+36.67%Maintains
a month ago
Compass Pathways PLCCMPS
2Strong Buy$21.00+58.01%Maintains
a month ago
Maplight Therapeutics IncMPLT
2Strong Buy$36.00+210.88%Maintains
2 months ago
Seaport Therapeutics IncSPTX
1Strong Buy$30.00+26.53%Initiates Coverage On
3 months ago
Sionna Therapeutics IncSION
2Strong Buy$55.00+740.98%Maintains
3 months ago
Immunic IncIMUX
1Strong Buy$25.00+50.78%Initiates Coverage On
4 months ago
Lb Pharmaceuticals IncLBRX
3Strong Buy$40.00-9.65%Maintains
5 months ago
Denali Therapeutics IncDNLI
4Strong Buy$41.00+65.19%Maintains
5 months ago
Kalvista Pharmaceuticals IncKALV
2Strong Buy$42.00+55.56%Maintains
5 months ago
Ionis Pharmaceuticals IncIONS
6HoldN/AN/AMaintains
6 months ago
Vertex Pharmaceuticals IncVRTX
16Hold$466.00-9.77%Maintains
6 months ago
Uniqure NvQURE
3Strong Buy$40.00-15.00%Maintains
8 months ago
Dyne Therapeutics IncDYN
5Strong Buy$39.00+50.23%Maintains
8 months ago
Neumora Therapeutics IncNMRA
3Hold$3.00+73.41%Maintains
9 months ago
Biomarin Pharmaceutical IncBMRN
11Hold$61.00-10.99%Downgrades
9 months ago
Biogen IncBIIB
7Strong Buy$202.00-4.11%Upgrades
9 months ago
Pepgen IncPEPG
3Strong Buy$12.00+302.68%Maintains
a year ago
Rhythm Pharmaceuticals IncRYTM
2Strong Buy$94.00N/AMaintains
a year ago
Vigil Neuroscience IncVIGL
2Hold$8.00N/ADowngrades
a year ago
Gh Research PLCGHRS
2Strong Buy$32.00N/AMaintains
a year ago
Sage Therapeutics IncSAGE
5Hold$6.00N/AMaintains
2 years ago
Alector IncALEC
5Hold$4.00N/ADowngrades
2 years ago
Alto Neuroscience IncANRO
3Strong Buy$10.00N/AMaintains
2 years ago
Neurogene IncNGNE
2Strong Buy$60.00N/AMaintains
2 years ago
Rapport Therapeutics IncRAPP
1Strong Buy$35.00N/AInitiates Coverage On
2 years ago
Contineum Therapeutics IncCTNM
1Strong Buy$29.00N/AInitiates Coverage On
2 years ago
Lexeo Therapeutics IncLXEO
1Strong Buy$20.00N/AInitiates Coverage On
3 years ago
Vistagen Therapeutics IncVTGN
1Strong Buy$12.00N/AInitiates Coverage On
3 years ago
Karuna Therapeutics IncKRTX
3Strong Buy$295.00N/AMaintains
4 years ago
Cerevel Therapeutics Holdings IncCERE
2Strong Buy$54.00N/AMaintains
4 years ago
Leonabio IncLONA
2Hold$50.00N/ADowngrades
4 years ago
Climb Bio IncCLYM
1Strong Buy$35.00N/AInitiates Coverage On
5 years ago
Acumen Pharmaceuticals IncABOS
1Strong Buy$27.00N/AInitiates Coverage On
5 years ago
Prevail Therapeutics IncPRVL
1Strong Buy$23.00N/AInitiates Coverage On
6 years ago
Gw Pharmaceuticals PLCGWPH
4Hold$140.00N/ADowngrades
6 years ago
Avadel Pharmaceuticals PLCAVDL
1Strong Buy$14.00N/AInitiates Coverage On
6 years ago
Zogenix IncZGNX
3Buy$60.00N/AInitiates Coverage On
8 years ago
Acorda Therapeutics IncACORQ
1Hold$2,280.00N/AMaintains
8 years ago
Akcea Therapeutics IncAKCA
2Hold$31.00N/AMaintains
8 years ago
Obseva SaOBSVF
1Buy$18.00N/AMaintains
8 years ago
Wave Life Sciences LtdWVE
1Buy$64.00N/AMaintains
8 years ago
Cidara Therapeutics IncCDTX
1Buy$340.00N/AInitiates Coverage On
10 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.